

Sabine Heitzeneder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1806512/publications.pdf>

Version: 2024-02-01

25
papers

1,852
citations

840776

11
h-index

996975

15
g-index

26
all docs

26
docs citations

26
times ranked

2979
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574. | 7.0 | 369 |
| 2 | Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, . | 12.6 | 297 |
| 3 | Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723. | 9.4 | 296 |
| 4 | Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719. | 30.7 | 172 |
| 5 | Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12. | 16.8 | 148 |
| 6 | Mannan-binding lectin deficiency " Good news, bad news, doesn't matter?. <i>Clinical Immunology</i> , 2012, 143, 22-38. | 3.2 | 146 |
| 7 | Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485. | 16.8 | 116 |
| 8 | Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344. | 30.7 | 105 |
| 9 | Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22. | 28.9 | 88 |
| 10 | GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. <i>Cancer Cell</i> , 2022, 40, 53-69.e9. | 16.8 | 60 |
| 11 | Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2019, 111, 970-982. | 6.3 | 43 |
| 12 | Abstract PR07: GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma and osteosarcoma. <i>Cancer Research</i> , 2020, 80, PR07-PR07. | 0.9 | 4 |
| 13 | Mannan-binding lectin deficiency attenuates acute GvHD in pediatric hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1127-1129. | 2.4 | 3 |
| 14 | IMMU-07. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, iv28-iv29. | 1.2 | 3 |
| 15 | IMMU-09. LOCALLY ADMINISTERED CAR T CELLS DEMONSTRATE MOST FAVORABLE ROUTE OF ADMINISTRATION IN A MODEL OF ATRT. <i>Neuro-Oncology</i> , 2019, 21, ii94-ii95. | 1.2 | 1 |
| 16 | Abstract PR04: Locoregionally administered B7H3-targeting CAR T cells mediate potent antitumor effects in atypical teratoid/rhabdoid tumor. , 2020, , . | | 1 |
| 17 | 327 B7-H3 Chimeric Antigen Receptor Modified T Cells Show Potent Anti-Tumor Activity in a Preclinical Model of Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 272. | 1.1 | 0 |
| 18 | IMMU-45. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi122-vi122. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | ATRT-25. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON ATYPICAL RHABDOID TERATOID TUMOR (ATRT) AND IS A PROMISING CANDIDATE FOR CAR T CELL THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i33-i33. | 1.2 | 0 |
| 20 | Abstract 1548: Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma. , 2021, , . | | 0 |
| 21 | Abstract 1357: Preferential expression of CD99 isoform variant 5 (CD99v005) in Ewing sarcoma compared to normal tissues. , 2015, , . | | 0 |
| 22 | Abstract 571: Pregnancy associated plasma protein A (PAPP-A) is a potential novel therapeutic target in Ewing sarcoma. , 2016, , . | | 0 |
| 23 | Abstract 1597: Inhibition of the novel therapeutic target pregnancy associated plasma protein A (PAPP-A) in Ewing sarcoma enhances efficacy of IGF1R targeting in vivo. , 2017, , . | | 0 |
| 24 | Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma. , 2017, , . | | 0 |
| 25 | Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity. , 2020, , . | | 0 |